Portola Pharmaceuticals (NASDAQ:PTLA) – Equities research analysts at William Blair dropped their FY2021 earnings estimates for Portola Pharmaceuticals in a research report issued on Friday, May 18th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will post earnings of $6.50 per share for the year, down from their prior estimate of $6.52. William Blair currently has a “Buy” rating on the stock.
Several other research analysts also recently weighed in on PTLA. ValuEngine downgraded shares of Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, May 11th. Oppenheimer set a $80.00 target price on shares of Portola Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday. Citigroup upped their target price on shares of Portola Pharmaceuticals to $64.00 and gave the stock a “buy” rating in a report on Monday, May 7th. BidaskClub raised shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, March 7th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $46.00 price objective (up previously from $31.00) on shares of Portola Pharmaceuticals in a report on Monday, May 7th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $64.86.
Shares of Portola Pharmaceuticals stock opened at $41.36 on Monday. The firm has a market capitalization of $2.72 billion, a P/E ratio of -8.60 and a beta of 1.48. The company has a quick ratio of 7.53, a current ratio of 7.59 and a debt-to-equity ratio of 0.35. Portola Pharmaceuticals has a fifty-two week low of $30.10 and a fifty-two week high of $67.10.
Portola Pharmaceuticals (NASDAQ:PTLA) last issued its earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, missing the consensus estimate of ($1.22) by ($0.06). The firm had revenue of $6.64 million during the quarter, compared to the consensus estimate of $3.20 million. Portola Pharmaceuticals had a negative return on equity of 109.35% and a negative net margin of 1,364.89%. The company’s quarterly revenue was up 29.7% on a year-over-year basis. During the same period in the prior year, the company posted ($0.74) EPS.
In related news, EVP Tao Fu sold 1,135 shares of the stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $38.47, for a total value of $43,663.45. Following the completion of the transaction, the executive vice president now owns 18,346 shares of the company’s stock, valued at approximately $705,770.62. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 4.60% of the stock is currently owned by company insiders.
Large investors have recently made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Portola Pharmaceuticals by 54.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,219 shares of the biopharmaceutical company’s stock worth $157,000 after purchasing an additional 1,141 shares during the period. SG Americas Securities LLC purchased a new stake in Portola Pharmaceuticals in the 1st quarter worth about $128,000. Penbrook Management LLC purchased a new stake in Portola Pharmaceuticals in the 4th quarter worth about $209,000. Dupont Capital Management Corp purchased a new stake in Portola Pharmaceuticals in the 4th quarter worth about $242,000. Finally, Oppenheimer & Co. Inc. purchased a new stake in Portola Pharmaceuticals in the 4th quarter worth about $256,000. 85.56% of the stock is owned by hedge funds and other institutional investors.
About Portola Pharmaceuticals
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily Factor Xa inhibitor for hospital and extended duration prophylaxis of venous thromboembolism in adults hospitalized for an acute medical illness; Andexanet alfa, a recombinant protein that is in Phase III study for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, a spleen tyrosine kinase inhibitor, which is in Phase IIa clinical stage to treat hematologic cancers.
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.